Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery
- 7 May 2017
- journal article
- research article
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 43 (9) , 1510-1518
Abstract
Objective: The aim of this work was to develop an amorphous solid dispersions/solutions (ASD) of a poorly soluble drug, budesonide (BUD) with a novel polymer Soluplus® (BASF, Germany) using a freeze-drying technique, in order to improve dissolution and absorption through the nasal route. Significance: The small volume of fluid present in the nasal cavity limits the absorption of a poorly soluble drug. Budesonide is a corticosteroid, practically insoluble and normally administered as a suspension-based nasal spray. Methods: The formulation was prepared through freeze-drying of polymer-drug solution. The formulation was assessed for its physicochemical (specific surface area, calorimetric analysis and X-ray powder diffraction), release properties and aerodynamic properties as well as transport in vitro using RPMI 2650 nasal cells, in order to elucidate the efficacy of the Soluplus–BUD formulation. Results: The freeze-dried Soluplus–BUD formulation (LYO) showed a porous structure with a specific surface area of 1.4334 ± 0.0178 m2/g. The calorimetric analysis confirmed an interaction between BUD and Soluplus and X-ray powder diffraction the amorphous status of the drug. The freeze-dried formulation (LYO) showed faster release compared to both water-based suspension and dry powder commercial products. Furthermore, a LYO formulation, bulked with calcium carbonate (LYO-Ca), showed suitable aerodynamic characteristics for nasal drug delivery. The permeation across RPMI 2650 nasal cell model was higher compared to a commercial water-based BUD suspension. Conclusions: Soluplus has been shown to be a promising polymer for the formulation of BUD amorphous solid suspension/solution. This opens up opportunities to develop new formulations of poorly soluble drug for nasal delivery.Keywords
This publication has 43 references indexed in Scilit:
- Non-invasive insight into the release mechanisms of a poorly soluble drug from amorphous solid dispersions by confocal Raman microscopyEuropean Journal of Pharmaceutics and Biopharmaceutics, 2016
- Bioequivalence for Locally Acting Nasal Spray and Nasal Aerosol Products: Standard Development and Generic ApprovalThe AAPS Journal, 2013
- Budesonide/cyclodextrin complex-loaded lyophilized microparticles for intranasal applicationDrug Development and Industrial Pharmacy, 2013
- Nasal drug delivery — Recent developments and future prospectsJournal of Controlled Release, 2012
- Characterization and in vitro evaluation of freeze-dried microparticles composed of granisetron–cyclodextrin complex and carboxymethylcellulose for intranasal deliveryInternational Journal of Pharmaceutics, 2010
- Nanoparticles for direct nose-to-brain delivery of drugsInternational Journal of Pharmaceutics, 2009
- Intranasal delivery: Physicochemical and therapeutic aspectsInternational Journal of Pharmaceutics, 2007
- Nasal drug delivery—possibilities, problems and solutionsJournal of Controlled Release, 2003
- Effect of Variable Inspiratory Flow Rate on the Performance of the Budesonide Rhinocort Turbuhaler???Clinical Drug Investigation, 2001
- Effects of physicochemical properties and other factors on systemic nasal drug deliveryAdvanced Drug Delivery Reviews, 1998